Status:
COMPLETED
Observational Study on CML Patients in Any Phase of the Disease Treated With Ponatinib (Iclusig®)
Lead Sponsor:
Incyte BioSciences France
Conditions:
Chronic Myeloid Leukemia
Eligibility:
All Genders
18+ years
Brief Summary
This is a multicentre ambispective cohort study involving French patients who have started or are receiving for less than 6 months a treatment with ponatinib. This study aims at better qualifying the ...
Eligibility Criteria
Inclusion
- Presenting a CML in any phase.
- Having initiated for less than six months a treatment with ponatinib.
- The ability to understand the requirements of the study and to comply with the study data collection procedures.
Exclusion
- Patients previously treated with investigational ponatinib (within a clinical trial).
- Patients receiving an investigational agent.
- Patients who are pregnant and/or breastfeeding.
- Patients with contraindications for Ponatinib according to Summary of Products Characteristics.
Key Trial Info
Start Date :
February 23 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 3 2023
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT04048564
Start Date
February 23 2018
End Date
July 3 2023
Last Update
September 28 2023
Active Locations (40)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU SUD Reunion GHSR
Saint-Pierre, Reunion, France, 97410
2
CHU Amiens-Picardie- Site SUD
Amiens, France, 80054
3
CHU D'Angers
Angers, France, 49100
4
CH Annecy
Annecy, France, 74370